ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None20232022202120202019201820172016 December 17, 2020 miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease November 10, 2020 miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates October 28, 2020 miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc. October 5, 2020 miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL) September 14, 2020 miRagen Announces Leadership Transition and Review of Strategic Alternatives August 20, 2020 miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL August 5, 2020 miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates August 4, 2020 miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference July 28, 2020 miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics July 23, 2020 Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 24
Year None20232022202120202019201820172016 December 17, 2020 miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease November 10, 2020 miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates October 28, 2020 miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc. October 5, 2020 miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL) September 14, 2020 miRagen Announces Leadership Transition and Review of Strategic Alternatives August 20, 2020 miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL August 5, 2020 miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates August 4, 2020 miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference July 28, 2020 miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics July 23, 2020 Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 24
December 17, 2020 miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
November 10, 2020 miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
October 5, 2020 miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)
August 20, 2020 miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL
July 28, 2020 miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics
July 23, 2020 Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma